- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/78 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Patent holdings for IPC class C07D 211/78
Total number of patents in this class: 117
10-year publication summary
|
9
|
19
|
10
|
7
|
6
|
5
|
7
|
4
|
7
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4789 |
6 |
| Global Blood Therapeutics, Inc. | 176 |
6 |
| California Institute of Technology | 4023 |
5 |
| The Broad Institute, Inc. | 1948 |
4 |
| Coral Sunscreen Pty Ltd | 5 |
4 |
| H. Lundbeck A/S | 1242 |
4 |
| Novartis AG | 10338 |
3 |
| The Regents of the University of California | 20590 |
3 |
| Bayer AG | 3470 |
3 |
| Cedars-Sinai Medical Center | 1189 |
3 |
| Entasis Therapeutics Limited | 33 |
3 |
| Orion Corporation | 751 |
3 |
| Delix Therapeutics, Inc. | 34 |
3 |
| Shenzhen Lcybetel Biological Technology Co.，ltd | 3 |
3 |
| Specialty Operations France | 894 |
3 |
| Genentech, Inc. | 4090 |
2 |
| Merck Sharp & Dohme Corp. | 2183 |
2 |
| Takeda Pharmaceutical Company Limited | 2718 |
2 |
| FMC Corporation | 816 |
2 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 861 |
2 |
| Other owners | 51 |